In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 2031-2040

  Aytac, Ugur ^a   McKee, Kathryn S ^a   Cabanillas, Fernando ^a   Ho, Linus ^a   Neumann, Christopher ^a   Abbruzzese, James L ^a   Mills, Gordon B ^a   LaPushin, Ruth ^a   Dang, Nam H ^a   Stephens, L Clifton ^b   Ohnuma, Kei ^c   Morimoto, Chikao ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Tokyo ^*

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1F7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CLASSIFICATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; T CELL LYMPHOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD26; ANTINEOPLASTIC AGENTS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G1 PHASE; HUMANS; LYMPHOMA, LARGE-CELL, KI-1; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEINS; S PHASE; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034776255     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. The structure and function of CD26 in the T-cell immune response
2. Dipeptidyl-peptidase IV/CD26 on T cells: Analysis of an alternative T-cell activation pathway
3. Regulation of the receptor specificity and function of the chemokine RANTES (Regulated on Activation, Normal T cells Expressed and Secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage
4. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV: Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1 infection
5. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response
6. Direct association of adenosine deaminase with a T cell activation antigen, CD26
7. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase
8. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody
9. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells
10. FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation
11. Co-mitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways
12. Human CD4 helper T cell activation: Functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family
13. 1F7 (CD26): A marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation
14. A novel pathway of human T cell activation via a 103 KD T cell activation antigen
15. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase
16. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody: Analysis of surface expression and human T cell activation
17. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes
18. Early phosphorylation events induced by DPPIV/CD26-specific inhibitors
19. Involvement of dipeptidyl peptidase IV in an in vivo immune response
20. Anti-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1 phase of the cell cycle
21. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias
22. CD26/dipeptidyl peptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas
23. All aboard the cyclin train: Subcellular trafficking of cyclins and their CDK partners
24. WAF1, a potential mediator of p53 tumor suppression
25. p21 is a universal inhibitor of cyclin kinases
26. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
27. 1 arrest and apoptosis
28. Transforming growth factor B induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism
29. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene
30. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts
31. Biochemical characterization of CD26 (dipeptidyl peptidase IV): Functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies
32. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill
33. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells
34. Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function
35. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis
36. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis
37. Increment in the Ta1 + cells in the peripheral blood and thyroid tissue of patients with Graves' disease
38. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis
39. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients
40. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma
41. CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma
42. Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia
43. Intravenous monoclonal antibody (BT5/9) for the treatment of acute graft-versus-host disease
44. Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster